Jeff Aronin is the C.E.O of Lundbeck and a renowned person in the field of medicine. He is a highly educated physician being an alumnus of Northern Illinois University and DePaul University where he acquired a bachelor degree and an MBA respectively.
After completing his education, Jeff worked in healthcare. He felt the need to help the neglected patients in the society who were suffering from rare diseases. In 2000, he founded and became the C.E.O of Ovation Pharmaceuticals LLC. Ovation pharmaceuticals had only one goal to focus on which was developing drugs for addressing smaller neglected diseases.
Though the company started with little capital, it gained popularity and grew tremendously. In 2009; Jeff sold the company to Lundbeck, which is a Danish healthcare company. Due to his previous records of being a successful leader, the company decided to retain him as the C.E.O of Lundbeck.it is through his experience, insight and exceptional leadership that has made Lundbeck succeed in the healthcare business.
One of the significant contributions of Jeff Aronin to the field of medicine is the establishment of Paragon Bioscience. The company has become a relief to people suffering from some diseases that were currently untreatable or those that had few options in treating them. It has focused on the creation of medical companies that would develop new medicines to cater for patients with these rare diseases.
Paragon work by identifying what the patient is suffering from through various test and what prescription he/she needs to get better. It provided financial support to biotechnological companies who are willing and dedicated to come up with new medicines. These medicines are used to cure hardly treatable disease and hence prolonging patients’ life.
Jeff Aronin is an entrepreneur who besides improving research for new medicines, he is dedicated to benefiting patients by helping them to acquire quality treatment through the latest scientifically discovered medicines
Through his efforts, Paragon has partnered with many other medical research companies. It has also networked with dedicated researchers, and he is optimistic that his leadership skills and experience will bring a cure to many patients.